{
    "response": "The long-term prognosis for your left eye primary acute angle-closure glaucoma (AACG) depends on several factors, including the timeliness of treatment, the extent of damage to the optic nerve, and how well the intraocular pressure (IOP) is controlled moving forward. Based on your clinical data, you were diagnosed with acute angle-closure glaucoma in the left eye, which is a serious condition that requires prompt and effective management to prevent permanent vision loss. Here’s what you need to know about your prognosis and ongoing care: \n\n1. **Immediate Treatment and Its Impact**: Acute angle-closure glaucoma is an emergency, and the goal of initial treatment is to rapidly lower the IOP to prevent further damage to the optic nerve. Your treatment likely included medications to reduce IOP and possibly a laser peripheral iridotomy (LPI) to create a new pathway for fluid drainage in the eye. If the attack was treated promptly, the risk of severe vision loss is reduced. However, if there was significant optic nerve damage before treatment, some degree of permanent vision loss may remain. \n\n2. **Long-Term Management**: After the acute episode, ongoing monitoring and management are crucial. Even after successful treatment, you may still be at risk for chronic angle-closure glaucoma, where the IOP remains elevated over time. This requires regular follow-up visits with your ophthalmologist to monitor IOP, assess the optic nerve, and check for any progression of glaucoma. If the IOP remains elevated, you may need long-term use of glaucoma medications or additional surgical interventions. \n\n3. **Risk of Recurrence**: Without proper treatment, such as LPI, there is a risk of recurrent episodes of acute angle-closure. LPI significantly reduces this risk by preventing the angle from closing again. However, even after LPI, some patients may develop areas of peripheral anterior synechiae (PAS), where the iris sticks to the cornea, which can lead to chronic angle-closure glaucoma. Regular gonioscopy (a test to examine the drainage angle) is essential to monitor for this. \n\n4. **Vision and Quality of Life**: If the IOP is well-controlled and there is no further damage to the optic nerve, your vision can stabilize. However, if glaucoma progresses, it can lead to gradual vision loss, particularly in the peripheral vision. This can affect daily activities such as reading, driving, and walking. Vision rehabilitation and low-vision services may be helpful if significant vision loss occurs. \n\n5. **Next Steps**: It is important to adhere to your ophthalmologist’s recommendations for follow-up visits and any prescribed medications. If you experience symptoms such as eye pain, redness, or sudden vision changes, seek immediate medical attention. Additionally, discuss any concerns about medication adherence or side effects with your doctor, as consistent treatment is key to preserving your vision. \n\nIn summary, with timely treatment and careful long-term management, the prognosis for your left eye primary acute angle-closure glaucoma can be favorable. However, ongoing monitoring and adherence to your treatment plan are essential to prevent further vision loss and complications.",
    "context": [
        {
            "id": 0,
            "source": "Primary Angle-Closure Disease PPP",
            "content": "## APPENDIX 2. INTERNATIONAL STATISTICAL CLASSIFICATION OF DISEASES AND RELATED HEALTH\nPrimary angle-closure disease includes the entity of primary angle-closure glaucoma and related entities with the following ICD-10 classifications:\n| ICD-10 CM |                                                                                      |\n|-----------|--------------------------------------------------------------------------------------|\n| Primary angle-closure glaucoma (PACG) | H40.20X-                                                                  |\n| Acute angle-closure glaucoma (AACC)   | H40.211<br>H40.212<br>H40.213                                              |\n| Intermittent angle closure (PAC or PACG) | H40.231<br>H40.232<br>H40.233                                          |\n| Chronic angle-closure glaucoma (PACG) | H40.221<br>H40.222<br>H40.223                                             |\n| Residual stage of angle-closure glaucoma | H40.241<br>H40.242<br>H40.243                                         |\n| Anatomical narrow angle (PACS)        | H40.031<br>H40.032<br>H40.033                                             |\n| Plateau iris syndrome                 | H21.82                                                                    |\n| Primary angle closure (PAC) without glaucoma damage | H40.061<br>H40.062<br>H40.063                              |\nAACC = acute angle-closure crisis; PAC = primary angle closure; PACG = primary angle-closure glaucoma; CM = Clinical Modification used in the United States; (-) = 0, stage unspecified; 1, mild stage; 2, moderate stage; 3, severe stage; 4, indeterminate stage; PACS = primary angle-closure suspect.\n### Additional information for ICD-10 codes:\n- Certain ICD-10 CM categories have applicable 7th characters. The applicable 7th character is required for all codes within the category, or as the notes in the Tabular List instruct. The 7th character must always be the 7th character in the data field. If a code that requires a 7th character is not 6 characters, a placeholder X must be used to fill in the empty characters.\n- For bilateral sites, the final character of the codes in the ICD-10 CM indicates laterality. If no bilateral code is provided and the condition is bilateral, separate codes for both the left and right side should be assigned. Unspecified codes should be used only when no other code option available.\n- When the diagnosis code specifies laterality, regardless of which digit it is found in (i.e., 4th digit, 5th digit, or 6th digit):\n  - Right is always 1\n  - Left is always 2\n  - Bilateral is always 3\n## APPENDIX 3. ALGORITHM FOR THE MANAGEMENT OF PATIENTS WITH ACUTE ANGLE-CLOSURE CRISIS\n#### FIGURE: Algorithm for the Management of Patients with Presumed Acute Angle-Closure Crisis\nThe flowchart outlines the management of patients with presumed acute angle-closure crisis (AACC). Key steps include initiating medical therapy to break the attack and prepare for laser iridotomy, assessing whether the view is clear, and proceeding with treatment options based on evidence for secondary causes or primary angle-closure disease mechanisms. Additional treatments such as topical glycerin, compression, paracentesis, or iridoplasty are suggested to clear the view if necessary. The algorithm includes steps for laser peripheral iridotomy, incisional iridectomy, and follow-up with dark-room gonioscopy to assess angle opening. Detailed measures for controlled and uncontrolled intraocular pressure (IOP) are also described, considering both surgical and medical management options.\n**Key Abbreviations:**\n- **AACC**: acute angle-closure crisis\n- **ICE**: iridocorneal endothelial\n- **IOP**: intraocular pressure\n- **NVI**: neovascularization of the iris\n- **PACD**: primary angle closure disease\n*Note: Indicated for extensive synechial closure or optic nerve damage.*"
        },
        {
            "id": 1,
            "source": "Primary Angle-Closure Disease PPP",
            "content": "## Follow-up Evaluation\nThe recommendations for follow-up evaluations after iridotomy for angle closure apply to ongoing management of PACD and not to visits for other purposes. Following LPI, patients may have an open anterior chamber angle or an anterior chamber angle with a combination of open sectors with areas occluded by PAS. With or without glaucomatous optic neuropathy, patients with a residual open angle or a combination of open angle and some PAS should be followed at appropriate intervals to check for increasing PAS. Special attention should be given to repeat gonioscopy to determine interval changes such as increased extent of PAS or development of secondary angle closure from cataract progression and increased lens thickness. Subsequent follow-up intervals depend on the clinical findings and judgment of the treating ophthalmologist.\nIf IOP remains elevated long term and the patient develops PAC or PACG, then ongoing medical therapy to lower IOP may become necessary. In such a situation, follow-up procedures and intervals would be dictated by the same principles outlined in the Primary Open-Angle Glaucoma PPP. As in primary open-angle glaucoma, adherence to medical therapy may be handicapped when patients run out of medication, due to inadvertent drop wastage or inability to properly instill eyedrops, before they are permitted to refill their prescription. One study found this was more likely for patients who self-administered eyedrop medications when visual acuity was worse than 20/70 in either eye. However, according to a 2010 directive, patients with Medicare insurance may now refill their medication after they have completed at least 70% of the month, or approximately 21 days of therapy.\n## PROVIDER AND SETTING\nThe performance of certain diagnostic procedures (e.g., tonometry, perimetry, pachymetry, anterior segment imaging, optic disc imaging, and photography) may be delegated to appropriately trained and supervised personnel. However, the interpretation of results and medical and surgical management of disease require the medical training, clinical judgment, and experience of the ophthalmologist. Most diagnostic and therapeutic procedures can be undertaken safely on an outpatient basis. Hospitalization may be indicated for intensive treatment of an AACC so that patients can be monitored closely after surgical procedures associated with a high risk of serious short-term postoperative complications. It may also be indicated for patients who have experienced surgical complications or for patients who have special medical or social needs.\n## COUNSELING AND REFERRAL\nIf the diagnosis or management of PACD is in question or is refractory to treatment, consultation with or referral to an ophthalmologist with special training or experience in managing these conditions may be indicated. Patients with substantial visual impairment or blindness may benefit from appropriate vision rehabilitation and social services. More information on vision rehabilitation, including materials for patients, is available at [www.aao.org/smart-sight-low-vision](www.aao.org/smart-sight-low-vision).\n## SOCIOECONOMIC CONSIDERATIONS\nAt the individual patient level, research has demonstrated that glaucomatous vision loss can have a dramatic impact on a patient’s well-being. Patients with glaucoma may struggle with daily activities such as reading, walking, and driving. Performance of these activities deteriorates with worsening of glaucoma severity and when both eyes are affected. Studies have reported that patients with glaucoma are three times more likely to experience falls and six times more likely to be involved in motor vehicle collisions compared with controls. Quality of life is affected for patients with all stages of glaucoma, even those with early disease.\nThe costs of managing a chronic disease like glaucoma can be broken down into direct medical costs, direct nonmedical costs, and indirect costs. Direct costs include costs of visits to eye care providers, ancillary testing, and medical and surgical interventions. One study estimated that nearly $3 billion USD per year is spent on the direct medical costs for all forms of glaucoma. Direct nonmedical"
        },
        {
            "id": 2,
            "source": "Primary Open-Angle Glaucoma Suspect PPP",
            "content": "## Differential Diagnosis\nGlaucoma is a chronic, progressive optic neuropathy associated with several risk factors, including IOP, that contribute to damage. The characteristic acquired atrophy of the optic nerve and loss of retinal ganglion cells and their axons can result in progressive visual field loss. Other entities associated with optic disc damage or abnormalities of the visual field should be considered prior to accepting the diagnosis of glaucoma. These nonglaucomatous diseases (and examples) are categorized as follows:\n### Optic Disc Abnormalities\n- Anterior ischemic optic neuropathies\n- Optic nerve drusen\n- Myopic tilted optic nerves\n- Toxic optic neuropathies\n- Congenital disc anomalies (e.g., congenital pit, coloboma, periventricular leukomalacia, morning glory syndrome)\n- Leber hereditary optic neuropathy and dominant optic atrophy\n- Optic neuritis\n### Retinal Abnormalities\n- Age-related macular degeneration\n- Chorioretinal scars from panretinal photocoagulation\n- Retinitis pigmentosa\n- Retinal arterial and venous occlusions\n- Myelinated nerve fibers\n- Retinal colobomas\n### Central Nervous System Abnormalities\n- Compressive optic neuropathy\n- Demyelination from multiple sclerosis\n- Nutritional optic neuropathy\n## MANAGEMENT\n### Goals\nThe goals of managing patients with POAG suspect are as follows:\n- Monitor or lower IOP through treatment if an eye is likely to progress to POAG\n- Monitor for structural changes in the optic disc and retina (RNFL and/or macular analysis)\n- Monitor for functional changes of the optic nerve by assessing the visual field\nIntraocular pressure is the primary modifiable factor to reduce the risk of conversion to glaucoma in glaucoma suspects. The decision to begin treatment to lower IOP in the glaucoma suspect patient is complex and based on the ophthalmologist’s analysis of the examination results, risk assessment, and the patient’s preferences. The number and severity of risk factors present, the prognosis, the patient’s life expectancy, management plan, and likelihood that\nIn the OHTS, more than 90% of patients with ocular hypertension did not progress to glaucoma over 5 years, but treatment to lower IOP reduced the risk of developing POAG from 9.5% to 4.5%. Since therapy exposes patients to the risks, side effects, and expense of long-term treatment, the decision to begin treatment for a glaucoma suspect patient is particularly important. For some patients, the risk of developing POAG is sufficiently high to justify starting treatment. For example, untreated patients in the OHTS with a baseline IOP of 26 mmHg or above and a CCT of 555 μm or below had a 36% chance of developing optic nerve damage during long-term follow-up compared with a 2% risk for patients with a baseline IOP of less than 24 mmHg and a CCT greater than 588 μm. Whether or not a patient is treated, long-term monitoring for the development of glaucoma is essential.\nWhen treatment is appropriate, an effective medication regimen requires attention to its effect on IOP, side effects, and to the possibility of nonadherence to therapy. Laser trabeculoplasty can also be considered as primary therapy for ocular hypertension. The ophthalmologist should consider these issues in choosing a regimen that works well to lower IOP to the desired level with the fewest possible side effects. The diagnosis, number and severity of risk factors, prognosis and management plan, and likelihood of long-term therapy should be discussed with the patient."
        }
    ],
    "QuestionID": "1",
    "llm_name": "deepseek-chat",
    "Question": "What is the long-term prognosis for my left eye primary acute angle-closure glaucoma?",
    "clinical_data": {
        "Age": 79.0,
        "Gender": "Female",
        "AdmissionDate": "2024-06-30T00:00:00",
        "DischargeDate": "2024-07-05T00:00:00",
        "AdmissionDiagnosis": "1. Left eye primary acute angle-closure glaucoma; 2. Left eye senile cataract",
        "DischargeDiagnosis": "1. Left eye primary acute angle-closure glaucoma; 2. Left eye senile cataract",
        "ClinicalHistory": "Chief Complaint: Sudden onset of distending pain and blurred vision in the left eye for 4 days.\nHistory of Present Illness: Four days ago, the patient experienced sudden onset of distending pain in the left eye without obvious precipitating factors, accompanied by a rapid decrease in vision. Both distant and near vision were unclear, accompanied by irritative symptoms such as eye redness, photophobia, and tearing, as well as ipsilateral headache and nausea. Denied history of ocular trauma. Due to persistent unremitting symptoms, the patient came to our hospital today for treatment. After relevant examinations in the outpatient clinic, the patient was admitted with a provisional diagnosis of \"1. Primary acute angle-closure glaucoma in the left eye; 2. Bilateral pseudophakia.\" During the course of the illness, there was no fever or cough. Appetite and sleep were poor, but bowel movements and urination were normal.\nPast Medical History and Surgical/Trauma History: General condition: Generally healthy. Denied history of chronic diseases such as diabetes and coronary heart disease; denied history of blood transfusion and trauma. Denied history of infectious diseases such as hepatitis, tuberculosis, bacillary dysentery, and typhoid fever. Immunizations were completed on schedule. Denied known allergies to sulfonamides, streptomycin, gentamicin, penicillin, cephalosporins, other medications, or food.\nOphthalmic Examination: Vod 0.4 Vos 0.1. IOP OD Tn OS T+2. Right eye: conjunctiva without hyperemia, cornea clear, peripheral anterior chamber shallow, aqueous humor clear, pupil round, diameter approximately 3mm, light reflex (+), lens turbid, fundus visible with retina attached, no obvious hemorrhage or exudation seen. Left eye: conjunctival mixed hyperemia (++), corneal opacity and edema, subepithelial bullae, KP (-), anterior chamber shallow, peripheral anterior chamber <1/3 CT, aqueous flare (+), pupil round, diameter approximately 4mm, light reflex (+), lens turbid, fundus view obscured.",
        "DifferentialDiagnosis": "1. Acute iridocyclitis: Sudden onset of eye redness, eye pain, varying degrees of vision loss, intraocular pressure often not elevated, significant anterior chamber inflammatory reaction, pupil constricted and irregular in shape.\n2. Glaucomatocyclitic crisis: Patients are mostly young and middle-aged adults, intraocular pressure sharply increases, local irritation symptoms are relatively mild, anterior chamber is not shallow, angle is open, with mutton-fat keratic precipitates on the posterior cornea."
    },
    "llm_answer_type": "LLM_HypotheticalRAG_Response",
    "temperature": 0
}